(24/7 MARKET NEWS) – TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced this morning today that its lead therapeutic candidate, TTX-MC138, was delivered to brain tumors and effectively engaged its target in murine models bearing human glioblastoma multiforme (GBM) tumors, the most common and aggressive form of brain cancer.
TransCode Therapeutics is trading at $0.81, up $0.146 (+21.68%), on 2.47M premarket shares traded.
Its 52-week range is $0.4998 to $31.00. It looks like it wants to run to $1.50 and, if it can hold today’s gains, it may be able to reverse its long-term downward trend.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.